Taking that they have been given two slots at SNO, I think suggests they have some interesting news to deliver. We are still only halfwayish through a Phase 1 trial. But GBM patients have a very small survival rate, and most don't make it past 6 months. There is a chance some sign of efficacy may be indicated even with the low dose. Survival of Patient one to now would be significant, if it has happened. The second dose cohort started in May 21. But as you have said primary endpoints of the trial are safety. A sign of efficacy against a solid tumor would be great news.
I guess we find out soon.
CHM Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)